Webinar

Advancing Targeted Therapies: 3D Bone Marrow Niche and PDX Models for AML and Multiple Myeloma Research

July 23, 2025 - Session 1: 11am CEST, Session 2: 11am Pacific Time. 

Understanding the complexity of the tumor microenvironment is critical for advancing therapies in hematologic cancers. In this 30-minute expert-led webinar, discover how Crown Bioscience’s innovative 3D in vitro bone marrow niche models and robust PDX models for acute myeloid leukemia (AML) and multiple myeloma are transforming preclinical research.

Learn how our proprietary bone marrow niche models replicate key aspects of the in vivo environment, including stromal support, cytokine signaling, and cellular interactions, providing a physiologically relevant platform for drug screening and disease modeling.

We’ll also explore our PDX model capabilities for AML and multiple myeloma, highlighting how these clinically relevant systems preserve patient heterogeneity, support translational research, and offer powerful tools for therapeutic evaluation.

Join us at either session to learn how to:

• Model disease biology more accurately with 3D bone marrow niche systems that mimic the human hematopoietic microenvironment and enable functional drug testing in vitro.
  
  
• Advance preclinical oncology programs using PDX models for AML and multiple myeloma that retain patient-specific genetic and phenotypic features.
  
  
• Bridge the gap between discovery and clinical translation with integrated platforms for evaluating drug response, resistance mechanisms, and combination strategies.

Save Your Seat Now

Meet Our Presenters:

Talita Stessuk, PhD, Scientist II, BMN Platform Lead, Crown Bioscience

Talita works as scientist in the Ex Vivo Patient Tissue Platform. She holds a PhD in Biotechnology from the University of São Paulo (Brazil) and served as postdoctoral researcher in Radboud UMC and TUe (The Netherlands). She has a strong foundation in regenerative medicine and tissue regeneration. With an extensive background in pre-clinical and clinical research, Talita has experience in the application of mesenchymal stromal cells (MSCs) for regeneration of different tissues, including bone tissue engineering. At Crown Bioscience, Talita spearheaded the development of the 3D Bone Marrow Niche (BMN) platform, advancing research in hematological malignancies. She is an expert in advanced 3D culture systems, high throughput screening, high content image analysis, 3D immunofluorescence, and multi-color flow cytometry. Passionate about pushing the boundaries of scientific innovation, Talita is committed to reproducing the tumor microenvironment in order to optimize the pre-clinical screening of bone marrow cancers.

Gerold Feuer, PhD, Senior Director, Scientific Research & Innovation, Crown Bioscience

Dr. Feuer was one of the first investigators to establish ‘humanized’ mice as an in vivo model to characterize genetic determinants of human retroviral infections and pathogenesis (HTLV-1 and HIV-1), as a postdoc and Assistant Research Biologist at UCLA Medical Center. He established his academic laboratory in the Department of Microbiology and Immunology at SUNY Upstate Medical University, Syracuse, studying HTLV-1 and KSHV pathogenesis in humanized mice, as well as developing proprietary methods for isolating human hematopoietic (CD34+) stem cells, developing lentivirus vectors for transduction of human CD34+ cells. He established and served as the Director of SUNY UMU’s Center for Humanized SCID Mouse Models. HuMurine was founded in 2008 as a SUNY- academic spinoff company and was the first company to commercialize the humanized immune system mouse. HuMurine laboratory operations relocated to adjacent to the U.C. Davis Medical Center and Institute for Regenerative Cures in Sacramento, CA, in 2011. After running HuMurine, Dr. Feuer joined Crown Bioscience full time in 2021. He has an extensive background in the fields of human virology, immuno-oncology, lentiviral vector gene therapies and human hematopoietic stem cells.